Lenvima gets European approval for advanced, unresectable hepatocellular carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Eisai and Merck said the European Commission granted a marketing authorization for the oral receptor tyrosine kinase inhibitor Lenvima (lenvatinib), as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

Lenvima is the first new, first-line treatment for advanced or unresectable HCC in a decade to show an overall survival treatment effect by statistical confirmation of non-inferiority against standard of care.

Lenvima is marketed in Japan for the treatment of HCC and in the United States for the treatment of first-line unresectable HCC, and applications seeking approval for this indication have been submitted to additional countries.

Table of Contents

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login